The increasement of blood METRNL protein by insulin sensitizer rosiglitazone
10.12206/j.issn.2097-2024.202308053
- VernacularTitle:胰岛素增敏剂罗格列酮升高血液中镍纹样蛋白水平
- Author:
Fei XU
1
;
Jin CHEN
2
;
Zhiyong LI
1
Author Information
1. Department of Pharmacology, School of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. Department of Endocrinology, First Affiliated Hospital of Naval Medical University, Shanghai 200082, China.
- Keywords:
insulin sensitizer;
rosiglitazone;
METRNL;
insulin resistance
- From:
Journal of Pharmaceutical Practice and Service
2024;42(4):165-168
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of insulin sensitizer rosiglitazone on blood METRNL levels. Methods After fed with high fat diet (HFD) for 3 months, obese mice were treated with rosiglitazone for 1 month. Glucose tolerance was tested with glucose tolerance test (GTT), and METRNL levels in blood were measured by ELISA. Real time fluorescence quantitative PCR was used to detect the expression of METRNL in various tissues such as muscle, liver, white fat, brown fat, brain, spleen and kidney, as well as the expression of mitochondrial proteins in brown adipose tissue. Results Glucose tolerance of animals fed a high-fat diet was improved in rosiglitazone group, and blood METRNL levels were also increased significantly in this group. Rosiglitazone treatment increased the expression of METRNL in brown fat and kidney tissue. There was no effect on METRNL expression in muscle, liver, white fat, brain and spleen. Rosiglitazone increased the expression of mitochondrial-associated proteins in brown adipose tissue. Conclusion The insulin sensitizer rosiglitazone might increase the serum METRNL level by increasing the METRNL expression in brown fat and kidney tissue, suggesting that METRNL may be involved in the therapeutic effect of rosiglitazone on diabetes.
